For Advanced Lung Cancer, Immune Therapy Plus Chemo Prolongs Survival | Latest News RSS feed

For Advanced Lung Cancer, Immune Therapy Plus Chemo Prolongs Survival - Latest News


For advanced lung cancer, immune therapy plus chemo prolongs survival

Patients with newly diagnosed advanced lung cancer who received an immunotherapy drug plus standard chemotherapy lived significantly longer than those who got chemo alone, according to a new study ... read more

New hope for lung cancer patients Study: Immunotherapy plus chemo prolongs survival

Patients with newly diagnosed advanced lung cancer who received an immunotherapy drug plus ... therapy group who were alive and whose disease had not gotten worse at a year was about 34 percent, about ... read more

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

First-line therapy for advanced non–small-cell lung cancer ... chemotherapy as the first-line treatment of choice. The addition of pembrolizumab to chemotherapy resulted in significantly higher rates ... read more

Looking for another news?


Immunotherapy Drug Significantly Boosts Odds Of Survival For Lung Cancer Patients

(Loftus and Rockoff, 4/16) The Washington Post: For Advanced Lung Cancer, Immune Therapy Plus Chemo Prolongs Survival Scientists who weren't involved in the study agreed that it was highly significant ... read more


FDA approves Merck’s Keytruda plus Inlyta to treat advanced renal cell carcinoma

Keytruda is an anti-PD-1 therapy, while Inlyta is a tyrosine kinase inhibitor. Keytruda will help enhance the ability of the body’s immune ... cancer and further supports the use of KEYTRUDA to help ... read more

Pembrolizumab Plus Chemo Improved Survival in Advanced NSCLC

The addition of the immune checkpoint inhibitor pembrolizumab to chemotherapy yielded significantly longer overall survival (OS) than chemotherapy alone in patients with newly diagnosed metastatic ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us